Business Wire

IQM Quantum Computers Acquires Assets of Quantistry GmbH to Bridge the Gap Between Quantum Algorithms and Solutions for Industrial Enterprises

6.7.2026 15:00:00 EEST | Business Wire | Press release

Share

IQM Quantum Computers (Nasdaq: IQMX) (“IQM”, “IQM Quantum Computers” or the “Company”), a global leader in full-stack superconducting quantum computers, has acquired selected assets of Quantistry GmbH, a Berlin-based developer of cloud-native simulation workflow platform for automotive, aerospace, chemical, materials and pharmaceutical industries.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260706448170/en/

IQM Quantum Computers Acquires Assets of Quantistry GmbH to bridge the gap between Quantum Algorithms and Solutions for Industrial Enterprises

The acquired assets include proprietary software applications, algorithms, and intellectual property. IQM will also retain Quantistry's core technical, quantum chemistry, and software engineering talent, ensuring seamless continuity and rapid platform integration.

The transaction completed recently, concurrently with IQM's business combination with Real Asset Acquisition Corp. (RAAQ), which made IQM the first publicly listed quantum computer company from Europe.

This transaction integrates Quantistry's cutting-edge application software platform, algorithm simulation libraries, and user-friendly machine learning layer with IQM's hardware infrastructure, creating a powerful full-stack solution designed to accelerate industrial research and development across automotive, aerospace, chemicals, materials science, and pharmaceuticals.

"True commercialization of quantum computing requires more than powerful hardware. It requires a bridge between hardware, software, and real industrial applications. The acquisition of Quantistry’s software assets builds that bridge,” said Jan Goetz, CEO and Co-Founder of IQM Quantum Computers. “It accelerates our software development timeline in a capital-efficient way, and brings in a technical team whose expertise will help us deliver cloud-accessible simulation value to enterprise customers. This is the kind of move that gets us there faster.”

The acquisition positions IQM to actively engage an exceptional roster of industrial leaders. The company plans to transition and expand these enterprise relationships under the IQM brand, offering clients a continuum of classical simulation, AI-driven optimization, and quantum acceleration — with a clear path to continuously upgrade their systems, optimize their operations, and deliver innovative, cutting-edge solutions to their own customers. This is Production Quantum in practice: enterprises do not just access a quantum computer, they own, operate, and grow with one.

Dr. Marcel Quennet, Co-Founder and CEO of Quantistry, said: “Joining forces with IQM Quantum Computers represents a monumental next chapter for our technology and the industry. IQM’s world-class quantum, hardware infrastructure and deep institutional trust provide the ultimate launchpad to scale our simulation platform. Together, we will enable R&D teams to model complex molecular and physical properties with unprecedented speed, moving from theoretical simulation to market-ready material innovation faster than ever before.”

Quantistry has established itself as an innovative force by building an intuitive cloud platform that leverages quantum mechanics, chemical simulations, and high-performance computing. A core differentiator of Quantistry’s technology is its proprietary Machine Learning (ML) and Artificial Intelligence (AI) layer, which allows a user without deep expertise in Quantum Computing or chemical simulation to create and simulate chemical compounds with accuracy on demand.

This framework automatically determines the most efficient computational pathways, seamlessly directing complex workflows across classical HPC infrastructures, native AI computing environments, and quantum backends.

Quantistry’s software will connect directly to IQM’s quantum computers. Industrial clients can build a proof of concept inside the IQM ecosystem, then scale it as the hardware improves, without switching platforms or starting over.

About IQM Quantum Computers

IQM Quantum Computers (Nasdaq: IQMX) is a global leader in superconducting quantum computers, delivering full-stack quantum systems and cloud platform access to enterprises, research institutions, universities, high-performance computing centers, and national laboratories worldwide. IQM's on-premises deployment model gives customers direct ownership and control of their quantum infrastructure. Founded in 2018 and headquartered in Finland, with major operations in Munich, IQM employs over 400 people and operates across Europe, Asia, and North America. IQM is the first publicly listed European quantum company on Nasdaq Stock Market.

About Quantistry GmbH

Quantistry is a leading provider of cloud-native chemical and materials simulation software. By combining high-performance computing (HPC), quantum chemical algorithms, and an intelligent machine-learning framework, Quantistry simplifies and accelerates the discovery of next-generation materials. Its platform serves key industries, including automotive, aerospace, energy storage, and pharmaceuticals, helping R&D teams innovate with greater speed and predictability.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260706448170/en/

Contacts

Media contact:
Michael Bruce
PR Manager
press@iqm.tech

Investor contact:
Blair Robertson
Vice President, Strategy & Corporate Development
Investor Relations Officer
investors@iqm.tech

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

www.businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 20:52:00 EEST | Press release

International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he has served as pro bono counsel to five Nobel Peace Prize laureates. The New York Times has referred to him as "The Extractor" for his work freeing political prisoners worldwide. Genser's decision to support Yim Leak's team comes as the businessman faces an asset freeze exceeding 20 billion baht (more than U

Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 18:38:00 EEST | Press release

Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co

Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli ® (Relacorilant)18.9.2026 15:00:00 EEST | Press release

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth

Enhertu ® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 15:00:00 EEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at the 2025 European Society for Medical Oncology (#ESMO25) Congress and subsequently published in The New England Journal of Medicine. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In DES

CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca ® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 13:58:00 EEST | Press release

Alfasigma S.p.A, a global pharmaceutical company with a focus on innovation in rare disease and specialty care in areas where there is significant unmet patient need, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Jyseleca® (filgotinib), an oral, once-daily JAK1 preferential inhibitor, for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy. Following this positive opinion, the application is now referred to the European Commission (EC) for final action. The EC’s decision is expected in the next weeks. “At present, half of people living with axSpA fail to adequately respond to treatment, leaving them with years of preventable struggle with persistent pain and other impactful symptoms,” said Daniele D'Ambrosio, Chief Development Officer, Alfasigma. “This

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye